HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a price target of $36.
September 19, 2024 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for 4D Molecular Therapeutics and maintained a price target of $36, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $36 price target by HC Wainwright & Co. suggests positive sentiment and confidence in 4D Molecular Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100